Three new studies from WCLC 2026 show strong results in ROS1-positive NSCLC, EGFR-mutant NSCLC and relapsed small cell lung cancer, offering fresh options.
|Videos|March 14, 2017
Kathleen N. Moore Discusses New PARP Inhibitors for Ovarian Cancer
Author(s)Kathleen N. Moore M.D.
Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.
Advertisement
Kathleen N. Moore, M.D., assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses developing new PARP inhibitors for patients with ovarian cancer. These new drugs may meaningfully prolong survival from a couple months to potentially years.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Welireg Plus Lenvima for Advanced Kidney Cancer After Immunotherapy
2
7 Breast Cancer Clinical Trials Currently Enrolling in the US
3
What to Do Before Your Chemo Infusion: A Checklist From People Who've Been There
4
How Paxalisib Targets Treatment Resistance in Breast Cancer
5